Stock AEVI GENOMIC MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Aevi Genomic Medicine, Inc.

Equities

US00835P1057

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index
CI
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Aevi Genomic Medicine, Inc. Announces Resignation of Directors
CI
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index
CI
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..
CI
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial
CI
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.
CI
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination
PR
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
PR
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)
CI
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference
PR
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Aevi Genomic Medicine, Inc.